RET+ NSCLC
Specialty Channel

Featured Article
Researchers combining selpercatinib with crizotinib were able to target MET-amplified resistance among patients with RET+ NSCLC treated with selpercatinib alone.
Selpercatinib was shown to be effective, with manageable safety, in patients with RET+ medullary thyroid cancer in a phase 1/2 trial.
Which of the following applications were recently granted accelerated approval by the FDA for adult and pediatric advanced or metastatic RET-altered thyroid cancer requiring systemic therapy?
The FDA has approved pralsetinib for the treatment of adult and pediatric patients with RET-mutated thyroid cancer.
True or False: In a phase 2 clinical trial, pembrolizumab plus docetaxel did not improve overall response rates and progression-free survival in pretreated patients with NSCLC.
In a phase 2 study of pretreated patients with NSCLC, pembrolizumab plus docetaxel substantially improved overall response rates and PFS.

News

Researchers combining selpercatinib with crizotinib were able to target MET-amplified resistance among patients with RET+ NSCLC treated with selpercatinib alone.
Selpercatinib was shown to be effective, with manageable safety, in patients with RET+ medullary thyroid cancer in a phase 1/2 trial.
The FDA has approved pralsetinib for the treatment of adult and pediatric patients with RET-mutated thyroid cancer.
In a phase 2 study of pretreated patients with NSCLC, pembrolizumab plus docetaxel substantially improved overall response rates and PFS.

Interactive Features

Which of the following applications were recently granted accelerated approval by the FDA for adult and pediatric advanced or metastatic RET-altered thyroid cancer requiring systemic therapy?
True or False: In a phase 2 clinical trial, pembrolizumab plus docetaxel did not improve overall response rates and progression-free survival in pretreated patients with NSCLC.
Stay in the know.
OncNet Newsletter